Diphenoxylate

No overview information is recorded for this medicine yet.

No indications information is recorded for this medicine yet.

No contraindications information is recorded for this medicine yet.

No side effects information is recorded for this medicine yet.

Do not use in patients with diarrhea caused by poisoning until the toxic material is eliminated from the GI tract by gastric lavage or cathartics. Do not use in patients with high fever or blood in stools. Overdosage may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death. Adhere strictly to dosage recommendations. Respiratory depression is possible up to 30 hours after ingestion and may recur despite initial response to an opiate antagonist. Because diphenoxylate is structurally similar to meperidine, consider the possibility of hypertensive crisis if diphenoxylate and MAO inhibitors are used concomitantly. Appropriate fluid and electrolyte replacement therapy is recommended, when indicated. If severe dehydration or electrolyte imbalance is present, withhold diphenoxylate until appropriate corrective therapy has been initiated. Drug-induced inhibition of peristalsis may result in fluid retention in the intestine, which may further aggravate dehydration and electrolyte imbalance; may mask fluid and electrolyte depletion in treatment of acute enteritis, especially in young children. Antiperistaltic agents may prolong and/or worsen diarrhea resulting from some infections (e.g., those caused by Shigella , Salmonella , toxigenic Escherichia coli ) and from pseudomembranous enterocolitis associated with broad spectrum antibiotics; do not use in these conditions. Toxic megacolon reported with agents that inhibit intestinal motility or prolong intestinal transit time in some patients with acute ulcerative colitis. Carefully observe patients with acute ulcerative colitis; discontinue promptly if abdominal distention occurs or other adverse symptoms develop. Hepatic coma reported in patients with cirrhosis. Use with extreme caution in patients with cirrhosis, advanced hepatorenal disease, or abnormal liver function tests results. Contraindicated in patients with jaundice. Ensure accuracy of prescription; similarity in spelling of Lomotil (fixed combination of diphenoxylate hydrochloride and atropine sulfate) and Lamictal (lamotrigine, an anticonvulsant agent) may result in errors. Commercially available only in combination with atropine sulfate. Consider the cautions, precautions, and contraindications associated with atropine. Evidence of physical dependence not reported with recommended dosages. Possibility of dependence when given in high dosage. Category C. Active metabolite (diphenoxylic acid) may be distributed into milk; atropine is distributed into milk. Drug effects may occur in breast-fed infants. Caution advised if used in nursing women. Not recommended for children <2 years of age. Use particular caution in young children due to greater variability of responses to the drug. Consider nutritional status and degree of dehydration. (See Fluid and Electrolyte Replacement Therapy under Cautions.) Not recommended for treatment of travelers’ diarrhea in infants, children, or adolescents with HIV infection. Consider precautions related to use of atropine in children; use with caution since signs of atropinism may occur even at recommended dosages, particularly in patients with Down’s syndrome. Use with extreme caution in patients with cirrhosis, advanced hepatorenal disease, or abnormal liver function test results, since hepatic coma may be precipitated. Contraindicated in patients with jaundice.

Do not use in patients with diarrhea caused by poisoning until the toxic material is eliminated from the GI tract by gastric lavage or cathartics. Do not use in patients with high fever or blood in stools. Overdosage may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death. Adhere strictly to dosage recommendations. Respiratory depression is possible up to 30 hours after ingestion and may recur despite initial response to an opiate antagonist. Because diphenoxylate is structurally similar to meperidine, consider the possibility of hypertensive crisis if diphenoxylate and MAO inhibitors are used concomitantly. Appropriate fluid and electrolyte replacement therapy is recommended, when indicated. If severe dehydration or electrolyte imbalance is present, withhold diphenoxylate until appropriate corrective therapy has been initiated. Drug-induced inhibition of peristalsis may result in fluid retention in the intestine, which may further aggravate dehydration and electrolyte imbalance; may mask fluid and electrolyte depletion in treatment of acute enteritis, especially in young children. Antiperistaltic agents may prolong and/or worsen diarrhea resulting from some infections (e.g., those caused by Shigella , Salmonella , toxigenic Escherichia coli ) and from pseudomembranous enterocolitis associated with broad spectrum antibiotics; do not use in these conditions. Toxic megacolon reported with agents that inhibit intestinal motility or prolong intestinal transit time in some patients with acute ulcerative colitis. Carefully observe patients with acute ulcerative colitis; discontinue promptly if abdominal distention occurs or other adverse symptoms develop. Hepatic coma reported in patients with cirrhosis. Use with extreme caution in patients with cirrhosis, advanced hepatorenal disease, or abnormal liver function tests results. Contraindicated in patients with jaundice. Ensure accuracy of prescription; similarity in spelling of Lomotil (fixed combination of diphenoxylate hydrochloride and atropine sulfate) and Lamictal (lamotrigine, an anticonvulsant agent) may result in errors. Commercially available only in combination with atropine sulfate. Consider the cautions, precautions, and contraindications associated with atropine. Evidence of physical dependence not reported with recommended dosages. Possibility of dependence when given in high dosage. Category C. Active metabolite (diphenoxylic acid) may be distributed into milk; atropine is distributed into milk. Drug effects may occur in breast-fed infants. Caution advised if used in nursing women. Not recommended for children <2 years of age. Use particular caution in young children due to greater variability of responses to the drug. Consider nutritional status and degree of dehydration. (See Fluid and Electrolyte Replacement Therapy under Cautions.) Not recommended for treatment of travelers’ diarrhea in infants, children, or adolescents with HIV infection. Consider precautions related to use of atropine in children; use with caution since signs of atropinism may occur even at recommended dosages, particularly in patients with Down’s syndrome. Use with extreme caution in patients with cirrhosis, advanced hepatorenal disease, or abnormal liver function test results, since hepatic coma may be precipitated. Contraindicated in patients with jaundice.

No adult dosage information is recorded for this medicine yet.

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Inhibits hepatic microsomal CYP isoenzymes at a dosage of 2 mg/kg daily.

No storage information is recorded for this medicine yet.